Jennifer Nielsen

Senior Vice President, Head of in vivo strategy at CRISPR Therapeutics

Role: Senior Vice President, Head of in Vivo Strategy at CRISPR Therapeutics
Location: Boston, MA, US
LinkedIn followers: 500 followers

Research & DevelopmentView LinkedIn profile

Experience

Senior Vice President, Head of in Vivo Strategy
CRISPR Therapeutics
Jan 2025 — Present

Education

University of New Hampshire
M.S.

Skills

Drug Development
Formulation
Clinical Trials
Project Management
R&D
Clinical Development
Pharmaceutical Process Development
Cross-Functional Team Leadership
Protein Chemistry
Cmc
Commercial
Certified Project Manager
Strategy

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@crisprtx.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

CRISPR Therapeutics

Biotechnology Research · 343 employees · Founded 2013 · Boston, Massachusetts, United States

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

crisprtx.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Experience

Senior Vice President, Head of in Vivo Strategy

Education

University of New Hampshire

Skills

Find verified contacts for anyone on LinkedIn